PJPer Bo Jensen

Per Bo Jensen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Per Bo Jensen has a total of 110 co-authors. Here are the top co-authors by number of shared publications:

  • Jens Juul Holst

    Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

    3 shared publications
  • Christopher B. Newgard

    Departments of Pharmacology and Cancer Biology, Medicine, and Biochemistry, Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center, Durham, NC 27704; ‡Department of Internal Medicine, Division of Endocrinology, University of Virginia Medical Center, Charlottesville, VA 22903; §Department of Internal Medicine, University of California, San Francisco, CA 94143; and ¶Section on Islet Transplantation and Cell Biology, Joslin Diabetes Center, Boston, MA 02215

    2 shared publications
  • Hal K. Berman

    From the ‡Departments of Biochemistry & Internal Medicine and Touchstone Center for Diabetes Research, University of Texas Southwestern Medical Center, Dallas, Texas 75235, the §Department of Cell Biology, Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105, and the ¶Department of Biochemistry, University of Indiana School of Medicine, Indianapolis, Indiana 46202

    2 shared publications
  • Jan Jensen

    Hagedorn Research Institute

    2 shared publications
  • Lars Thim

    2 shared publications
  • Mads Tang-Christensen

    Rheoscience, Glerupvej 2, 2610 Rødovre, Denmark

    2 shared publications

Latest Publications

  • Open Access

    Octreotide improves human lymphatic fluid transport a translational trial

    by Thomas Holm-Weber, Frederik Skov, Sheyanth Mohanakumar, Lene Thorup, Troels Riis, Mikkel Bring Christensen, David Peick Sonne, Per Bo Jensen, Donna Briggs Bødtkjer, Vibeke Elisabeth Hjortdal

    Chylothorax is a complex condition and many different pharmacological agents have been tried as treatment. Octreotide is used off-label to treat chylothorax, but the efficacy of octreotide remains unclear. A decrease in lymph production is suggested as the mechanism. In this cross-over study, we explore the direct effect of octreotide on human lymphatic drainage. Pre-clinical: the effect of octreotide on force generation was assessed during acute and prolonged drug incubation on human lymphatic vessels mounted in a myograph. Clinical: in a double-blinded, randomized, cross-over trial including 16 healthy adults, we administered either octreotide or saline as an intravenous infusion for 2.5 h. Near-infrared fluorescence imaging was used to examine spontaneous lymphatic contractions and lymph pressure in peripheral lymphatic vessels and plethysmography was performed to assess the capillary filtration rate, capillary filtration coefficient and isovolumetric pressures of the lower leg. Pre-clinical: human thoracic duct (n = 12) contraction rate was concentration-dependently stimulated by octreotide with a maximum effect at 10 and 100 nmol/l in the myograph chamber. Clinical: spontaneous lymphatic contractions and lymph pressure evaluated by near-infrared fluorescence did not differ between octreotide or placebo (P = 0.36). Plethysmography revealed similar capillary filtration coefficients (P = 0.057), but almost a doubling of the isovolumetric pressures (P = 0.005) during octreotide infusion. Octreotide stimulated lymphatic contractility in the pre-clinical setup but did not affect the spontaneous lymphatic contractions or lymph pressure in healthy individuals. Plethysmography revealed a doubling in the isovolumetric pressure. These results suggest that octreotide increases lymphatic drainage capacity in situations with high lymphatic afterload.


  • Polyethylenimine architecture-dependent metabolic imprints and perturbation of cellular redox homeostasis

    by Arnaldur Hall, Ladan Parhamifar, Marina Krarup Lange, Kathrine Damm Meyle, May Sanderhoff, Helene Andersen, Martin Roursgaard, Anna Karina Larsen, Per Bo Jensen, Claus Christensen, et al.


  • Open Access

    Microscale oxygraphy reveals OXPHOS impairment in MRC mutant cells

    by F. Invernizzi, I. D'AMato, P.B. Jensen, S. Ravaglia, M. Zeviani, V. Tiranti


  • Foetal proglucagon processing in relation to adult appetite control: lessons from a transplantable rat glucagonoma with severe anorexia

    by P. B. Jensen, P. J. Larsen, C. Karlsen, H. I. Jensen, J. J. Holst, O. D. Madsen

    We have previously reported severe anorexia abruptly induced in rats 2–3 weeks after they have been transplanted subcutaneously with the glucagonoma MSL‐G‐AN. Vagotomy did not affect the time of onset and severity of anorexia, and the anorectic state resembles hunger with strongly elevated neuropeptide Y (NPY) mRNA levels in the nucleus arcuatus. We now show that circulating levels of bioactive glucagon‐like peptide‐1 (GLP‐1) (7‐36amide) start to increase above control levels exactly at the time of onset of anorexia. At this time‐point, bioactive glucagon as well as total glucagon precursors and GLP‐1 metabolites are already vastly elevated compared to controls. We further show that intravenous administration of very high concentrations of GLP‐1 to hungry schedule‐fed rats causes anorexia in a dose‐dependent manner, which is blocked by the GLP‐1 receptor antagonist exendin (9‐39). GLP‐1 (7‐36amide) has a well‐characterized anorectic effect but also causes taste aversion when administered centrally. The anorectic effect is blocked in rats treated neonatally by monosodium glutamate (MSG). We show that MSG treatment does not prevent the MSL‐G‐AN‐induced anorexia, thereby suggesting a different type of anorectic function. We show a very strong component of taste aversion as anorectic rats, when presented to novel or known alternative food items, will resume normal feeding for 1 day, and then redevelop anorexia. We hypothetize that the anorexia in MSL‐G‐AN tumour‐bearing rats correlates with a foetal processing pattern of proglucagon to both glucagon and GLP‐1 (7‐36amide), and is due to taste aversion. The sudden onset is characterized by a dramatic increase in circulating levels of biologically active GLP‐1 (7‐36amide), suggesting eventual saturation of proteolytic inactivation of its N‐terminus.


  • Open Access

    Bioenergetic Profile Experiment using C2C12 Myoblast Cells

    by David G. Nicholls, Victor M. Darley-Usmar, Min Wu, Per Bo Jensen, George W. Rogers, David A. Ferrick

    A description of a method for profiling mitochondrial function in cells is provided. The mitochondrial profile generated provides four...


  • Upregulation of the brainstem preproglucagon system in the obese Zucker rat

    by Niels Vrang, Philip Just Larsen, Per Bo Jensen, Kirsten Lykkegaard, Andreas Artmann, Leif Kongskov Larsen, Mads Tang-Christensen


  • Biological effects of fruit and vegetables

    by Lars O. Dragsted, Britta Krath, Gitte Ravn-Haren, Ulla B. Vogel, Anne Marie Vinggaard, Per Bo Jensen, Steffen Loft, Salka E. Rasmussen, BrittMarie Sandstrom, Anette Pedersen

    A strong and persistent effect of plant-derived foods on the prevention of lifestyle diseases has emerged from observational studies. Several groups of constituents in plants have been identified as potentially health promoting in animal studies, including cholesterol-lowering factors, antioxidants, enzyme inducers, apoptosis inducers etc. In human intervention studies the dose levels achieved tend to be lower than the levels found to be effective in animals and sampling from target organs is often not possible. A controlled dietary human intervention study was performed with forty-three volunteers, providing 600 g fruit and vegetables/d or in the controls a carbohydrate-rich drink to balance energy intake. Surrogate markers of oxidative damage to DNA, protein and lipids, enzymic defence and lipid metabolism were determined in blood and urine. It was found that a high intake of fruit and vegetables tends to increase the stability of lipids towards oxidative damage. Markers of oxidative enzymes indicate a steady increase in glutathione peroxidase (GPX1) activity in erythrocytes during intervention with fruit and vegetables but there is no effect on GPX1 transcription levels in leucocytes. No change occurs in glutathione-conjugating or -reducing enzyme activities in erythrocytes or plasma, and there are no effects on the transcription of genes involved in phase 2 enzyme induction or DNA repair in leucocytes. Fruit and vegetable intake decreases the level of total cholesterol and LDL-cholesterol, but does not affect sex hormones. In conclusion, it has been shown that total cholesterol and LDL-cholesterol, markers of peripheral lipid oxidation, and erythrocyte GPX1 activity are affected by high intakes of fruit and vegetables. This finding provides support for a protective role of dietary fruit and vegetables against CVD.


  • The Nkx6.1 homeodomain transcription factor suppresses glucagon expression and regulates glucose-stimulated insulin secretion in islet beta cells

    by Jonathan C. Schisler, Per Bo Jensen, David G. Taylor, Thomas C. Becker, Filip Krag Knop, Shiro Takekawa, Michael German, Gordon C. Weir, Danhong Lu, Raghavendra G. Mirmira, et al.

    We have previously described rat insulinoma INS-1-derived cell lines with robust or poor glucose-stimulated insulin secretion (GSIS). In the current study, we have further resolved these lines into three classes: class 1, glucose-unresponsive/glucagon-expressing; class 2, glucose-unresponsive/glucagon-negative; and class 3, glucose-responsive/glucagon-negative. The transcription factor Nkx2.2 was expressed with relative abundance of 3.3, 1.0, and 1.0 in class 1, class 2, and class 3 cells, respectively, whereas Nkx6.1 expression had the opposite trend: 1.0, 2.6, and 6.4 in class 1, class 2, and class 3 cells, respectively. In class 1 cells, overexpressed Nkx6.1 suppressed glucagon expression but did not affect the levels of several other prominent beta cell transcription factors. RNA interference (RNAi)-mediated suppression of Nkx6.1 in class 3 cells resulted in a doubling of glucagon mRNA, with no effect on Pdx1 levels, whereas suppression of Pdx1 in class 3 cells caused a 12-fold increase in glucagon transcript levels, demonstrating independent effects of Nkx6.1 and Pdx1 on glucagon expression in beta cell lines. RNAi-mediated suppression of Nkx6.1 expression in class 3 cells also caused a decrease in GSIS from 13.9- to 3.7-fold, whereas suppression of Pdx1 reduced absolute amounts of insulin secretion without affecting fold response. Finally, RNAi-mediated suppression of Nkx6.1 mRNA in primary rat islets was accompanied by a significant decrease in GSIS relative to control cells. In sum, our studies have revealed roles for Nkx6.1 in suppression of glucagon expression and control of GSIS in islet beta cells.


  • Ups and downs for neuropeptides in body weight homeostasis: pharmacological potential of cocaine amphetamine regulated transcript and pre-proglucagon-derived peptides

    by Philip J Larsen, Niels Vrang, Mads Tang-Christensen, Per Bo Jensen, Anders Hay-Schmidt, John Rømer, Lotte Bjerre-Knudsen, Peter Kristensen


  • Open Access

    Distinctive Regulatory and Metabolic Properties of Glycogen-targeting Subunits of Protein Phosphatase-1 (PTG, GL, GM/RGl) Expressed in Hepatocytes

    by Rosa Gasa, Per B. Jensen, Hal K. Berman, Matthew J. Brady, Anna A. DePaoli-Roach, Christopher B. Newgard